# Phase 2 Diabetes Mellitus trials recruiting: 120 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 120 trials in phase 2 for Diabetes Mellitus that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Diabetes Mellitus trials: 120 rows for $6, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/diabetes-mellitus

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 120
- Recruiting or not yet: 120
- Read on: November 19, 2026

## Trials

The 25 newest of 120, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2026 | NCT07929350 | Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Therapy | Beijing Supreme Life Pharmaceutical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Diabetes Mellitus, Type 2 | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929350) |
| November 10, 2026 | NCT07928661 | Effect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 Diabetes | Universitas Sriwijaya | Phase 2 | Recruiting | Diabetes Mellitus, Type 2 | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928661) |
| November 6, 2026 | NCT07923357 | A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, T2DM | 364 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923357) |
| November 6, 2026 | NCT07922148 | Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Mild Autonomous Cortisol Secretion (MACS), Diabetes Mellitus (Type 2) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922148) |
| November 5, 2026 | NCT07920640 | Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Poor Glycemic Control Despite Lifestyle Intervention | Beijing Supreme Life Pharmaceutical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Diabetes Mellitus, Type 2 | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920640) |
| October 22, 2026 | NCT07889505 | A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 Diabetes | Pharmasaga Co. Ltd. | Phase 2 | Not yet recruiting | Type 1 Diabetes Mellitus | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889505) |
| October 22, 2026 | NCT07888426 | Tolerability and Safety of Nano-Tocotrienols | University of Malaya | Phase 2 | Not yet recruiting | Type 2 Diabetes Mellitus (DM) | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888426) |
| October 13, 2026 | NCT07872436 | A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control | Vincentage Pharma Co., Ltd | Phase 2 | Not yet recruiting | Type 2 Diabetes Mellitus (DM) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872436) |
| September 29, 2026 | NCT07845955 | JAK1 Inhibitor Ivarmacitinib for Improving Pancreatic Islet Function in T1D | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | T1DM - Type 1 Diabetes Mellitus | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845955) |
| September 28, 2026 | NCT07843862 | A Study of HRS-4729 Injection in Participants With Type 2 Diabetes | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Type 2 Diabetes | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843862) |
| September 24, 2026 | NCT07837934 | Colchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes | Tan Tock Seng Hospital | Phase 2 | Recruiting | Type 2 Diabetes Mellitus (T2DM), Atherosclerosis, Cardiovascular Diseases | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07837934) |
| September 8, 2026 | NCT07808151 | Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer | Solstice Oncology, Inc. | Phase 2 | Recruiting | Colon Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808151) |
| September 3, 2026 | NCT07801820 | Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus | Shanghai Minwei Biotechnology Co., Ltd | Phase 2 | Recruiting | Type 2 Diabetes Mellitus (T2DM) | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801820) |
| September 2, 2026 | NCT07798960 | Effects of Transcutaneous Photobiomodulation on Diabetic Foot Ulcers. | University of Nove de Julho | Phase 2 | Recruiting | Diabetes Mellitus, Foot Ulcer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07798960) |
| September 1, 2026 | NCT07796477 | A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | T2DM (Type 2 Diabetes Mellitus) | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796477) |
| August 25, 2026 | NCT07783802 | A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | Eli Lilly and Company | Phase 2 | Recruiting | Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783802) |
| August 12, 2026 | NCT07760948 | HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide | Vanderbilt University Medical Center | Phase 2 | Not yet recruiting | Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity, Muscle Loss, Older Adults | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760948) |
| August 10, 2026 | NCT07755150 | A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes | Chendu DIAO Pharmaceutical Group CO., LTD. | Phase 2 | Not yet recruiting | Type 2 Diabetes Mellitus | 272 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07755150) |
| August 5, 2026 | NCT07748208 | A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC)... | Hoffmann-La Roche | Phase 2 | Recruiting | Breast Cancer, Diabetes Type II | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748208) |
| July 13, 2026 | NCT07699380 | METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D) | University of Washington | Phase 2 | Recruiting | Type 1 Diabetes (T1D), Metabolic Diseases, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07699380) |
| July 6, 2026 | NCT07683026 | Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | Not yet recruiting | Type 1 Diabetes (T1D) | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683026) |
| July 1, 2026 | NCT07677891 | Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus | ProGen. Co., Ltd. | Phase 2 | Not yet recruiting | Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07677891) |
| June 25, 2026 | NCT07668388 | A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes | Novo Nordisk A/S | Phase 2 | Recruiting | Diabetes Mellitus, Type 2 | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668388) |
| June 1, 2026 | NCT07616206 | Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems | vTv Therapeutics | Phase 2 | Recruiting | Type 1 Diabetes (T1D) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616206) |
| May 29, 2026 | NCT07614412 | SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes. | Ministry of Health, Saudi Arabia | Phase 2 | Not yet recruiting | Type 1 Diabetes Mellitus | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614412) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 4 |
| Mayo Clinic | 3 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 2 |
| University of Washington | 2 |
| University of California, San Diego | 2 |
| Chinese University of Hong Kong | 2 |
| Beijing Supreme Life Pharmaceutical Technology Co., Ltd. | 2 |
| ProGen. Co., Ltd. | 2 |
| University of Florida | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 2 |
| AdventHealth Translational Research Institute | 2 |
| Sparrow Pharmaceuticals | 1 |
| Global Institute of Stem Cell Therapy and Research | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| Shanghai Jiao Tong University School of Medicine | 1 |
| [Gan & Lee Pharmaceuticals.](https://specstream.ai/data/clinical-trials/company/gan-and-lee-pharmaceuticals) | 1 |
| S1 Biopharma, Inc. | 1 |
| vTv Therapeutics | 1 |
| Arizona State University | 1 |
| [Shenzhen Salubris Pharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/shenzhen-salubris-pharmaceuticals-co-ltd) | 1 |
| Vanderbilt University Medical Center | 1 |
| University of Malaya | 1 |
| Medical College of Wisconsin | 1 |
| [Pharming Technologies B.V.](https://specstream.ai/data/clinical-trials/company/pharming-technologies-b-v) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 57 |
| China | 19 |
| Australia | 8 |
| Poland | 8 |
| United Kingdom | 7 |
| Canada | 6 |
| Denmark | 6 |
| Spain | 6 |
| Germany | 5 |
| South Korea | 4 |
| Belgium | 4 |
| France | 4 |
| Netherlands | 4 |
| Italy | 3 |
| Hungary | 3 |
| Puerto Rico | 3 |
| Finland | 2 |
| Slovakia | 2 |
| Croatia | 2 |
| Switzerland | 2 |
| Hong Kong | 2 |
| Brazil | 2 |
| Japan | 2 |
| Indonesia | 2 |
| Malaysia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Gluten free restaurants in the United States](https://specstream.ai/data/businesses/gluten-free-restaurants/united-states)
- [Home cleaning companies in the United States](https://specstream.ai/data/businesses/home-cleaning-companies/united-states)
- [Hydraulic equipment suppliers in the United States](https://specstream.ai/data/businesses/hydraulic-equipment-suppliers/united-states)
- [Internal medicine practices in the United States](https://specstream.ai/data/businesses/internal-medicine-practices/united-states)
- [Junk removal companies in the United States](https://specstream.ai/data/businesses/junk-removal-companies/united-states)
- [Lighting fixtures and equipment companies in the United States](https://specstream.ai/data/businesses/lighting-fixtures-and-equipment-companies/united-states)
